Vanrafia® (atrasentan) – New drug approval
April 3, 2025 - Novartis announced the FDA approval of Vanrafia (atrasentan), to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g.
Top